Urate-Lowering Treatments Compared for Gout


THURSDAY, July 7, 2022 — For relatively young and healthy patients with gout caused by renal underexcretion of uric acid, low-dose benzbromarone (LDBen) has a greater urate-lowering effect than low-dose febuxostat (LDFeb), according to a study published online July 7 in Arthritis & Rheumatology.

Fei Yan, M.D., from the Affiliated Hospital of Qingdao University in China, and colleagues conducted a randomized trial of men with gout and renal uric acid underexcretion. A total of 196 participants were randomly assigned to 12 weeks of LDBen 25 mg daily or LDFeb 20 mg daily (mean age, 43.89 and 43.29 years, respectively). All received daily urine alkalization with oral sodium bicarbonate.

The researchers found that more participants in the LDBen versus the LDFeb group achieved the serum urate target (<6 mg/dL; 61 versus 32 percent). There was no difference observed between the groups for adverse events, including gout flares and urolithiasis, with the exception of more participants with transaminase elevation in the LDFeb group (4 percent for LDBen versus 15 percent for LDFeb).

“The results suggest that low dosing of benzbromarone may warrant stronger consideration as a safe and effective therapy to achieve serum urate target in gout without moderate chronic kidney disease,” the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

© 2022 HealthDay. All rights reserved.

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.


Source link

Published by Drugs.Com Know More. Be Sure
Managed by Pharma Enthusiast, To claim this account, mail us at pharmamedia.in@gmailcom






0 responses to “Urate-Lowering Treatments Compared for Gout”

Get Connected!
Come and join Pharma Community. Expand your network in Pharma!


No comments yet